Drawing parallels with the continued optimization in the past century history of insulin, this article argues that the interfacial electrostatic scaffold here constitutes a robust framework for continued development of next-generation GLP-1R agonists, enabling more effective therapies for patients with diabetes and/or obesity
Fundamentals of SGLT2i's and GLP-1RA's for CV Risk Listen to Expert Faculty discuss the fundamental science and the mechanism to evidence around new antihyperglycemic drugs,
American College of Rheumatology
The tablet was approved by the MHRA on 11 June 2026 as the UK's first oral GLP-1 weight-loss medicine, but is not yet commercially available
While effective, it can cause side effects ranging from mild to serious, including oral thrush, headaches, sore throat, hoarseness, and rare adrenal suppression